Phase 3 trial of tobramycin inhalation powder in cystic fibrosis with Pseudomonas aeruginosa infection

Phase 3, randomised, double-blind trial in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection comparing Tobramycin inhalation powder with Placebo (2 arms). Primary endpoint: Relative change in FEV1 percent predicted from baseline to end of cycle 1 dosing. Started Aug 2005; status: completed.